Coherus announces positive Phase II results for liver cancer treatment
Coherus BioSciences shared final data from its Phase II trial…
Coherus BioSciences shared final data from its Phase II trial of casdozokitug, showing a 17.2 percent complete response rate in liver cancer patients.